Navigation Links
CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center
Date:2/27/2009

xisting portfolio of clinical and preclinical oncology programs. However, at present no alternative solution has been found.

Bresso employees were informed of the company's plans today. The company anticipates starting negotiations with the Trade Unions in the near future.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating anti-tumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

In January 2009, CTI announced that pixantrone met its primary endpoint of progression-free survival (PFS), and it expects to begin submission of a rolling NDA and request priority review for pixantrone to treat relapsed aggressive NHL in the first quarter of 2009.

About OPAXIO

CTI currently has one drug for lung cancer, OPAXIO(TM), awaiting approval in Europe. OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a ne
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Aegis Living Focuses On Taking Care of Their Own in 2009
2. Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009
3. Lumension Security's Audiocast Focuses on Evolving Threats and Countermeasures: Achilles Heel of Data Loss and Theft
4. EntreMed Focuses on Development of ENMD-2076
5. ITRI: Taiwan Focuses on C Liver Medic's R&D to Reach USD 6 Billion Potential Market in the World
6. Tragedy Focuses Spotlight on Crisis in North Carolina Mental Health System
7. Siemens Focuses on Role-Based, Context-Sensitive and Knowledge-Driven Solutions
8. Pivotal Emory study focuses on teens at risk for psychosis
9. New Veterans Drug Court Focuses on Rehabilitating Our Soldiers Through Mental Health Treatment
10. Lupus Live Web Chat Focuses on Medication Management
11. National Family Month 2008 Focuses on Top Issues Facing Kids and Families Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... lung cancer has won $ 1 million in a lottery. Wayne ... inoperable lung cancer. ,Doctors have given him a year ... he has won this lottery. But the irony that is accompanying ... annual installments over twenty years. ,Schenk is a chain ...
... University in Chicago claim that men who have undergone ... type// of dementia. This study was published in Cognitive ... on 106 men. Out of this, 25 developed a ... undergone vasectomy. According to the chief scientist of this ...
... that patients who develop Parkinson's disease in youth ... abuse may be more likely to develop pathological ... to treat their condition. ,Behaviors associated ... and pathological gambling—have been associated with dopamine agonists, ...
... sclerosis (MS) for 10 years and have few of the disabling ... and that their symptoms will likely not ever occur to the ... that unfortunately this may not be correct. ,After ... whose MS was benign at 10 years, according to the study. ...
... increased, there are still significant disparities in screening// practices. ... disparities are by ethnicity, sex, age, education and income ... most common cancer affecting men and women in the ... according to background information in the article. 'There is ...
... powerful two-gene test that can distinguish between a pair ... courses of treatment. ,Their report is published ... Proceedings of the National Academy of Sciences. ... be relatively quickly implemented in the clinic to benefit ...
Cached Medicine News:Health News:Compulsive Gambling Linked to Parkinson's Disease Medications 2Health News:Disparities in Colon Cancer Screening Remain Among Medicare Patients 2Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC ...  filed a Preliminary Proxy Statement, Schedule 14A, with the U.S. ... an update for shareholders detailing why a "YES" vote to ... Dear Shareholders, As we reflect upon the 2014 ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
Designed for peeling delicate epiretinal membrane in cases of premacular fibroplasia. Positive action closure. Barrel design with straight 20 gauge 40 gauge long shaft. 1 x 1.5 mm lightly serrated ja...
Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm jaws. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Blackened tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. 2 mm pointed tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Angled shafts with 9 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Right....
Medicine Products: